This licensing agreement further enhances our intellectual property estate of more than 40 patents and patent applications relating to active immunotherapy
and monoclonal antibodies," said Manish Singh, Ph.
As the principal investigator for the BiovaxID clinical trials and as a key consultant to Biovest, his contributions are largely responsible for positioning the Company to seek approvals for BiovaxID as a first-in-class active immunotherapy
for the treatment of follicular non-Hodgkin's lymphoma.
Participants in the study will be given either the active immunotherapy
, the BACE inhibitor or placebo.
In terms of active immunotherapy
and the type of technology we're developing, they've undergone an evolution in the last three or four years.
Open sessions will focus on today's hottest oncology issues along with updated information on new drugs, evidence-based practice, patient teaching, secondary cancers, acute leukemia, hereditary cancers, genetics, active immunotherapy
, multisite research, symptom management, pain management, end-of-life care, targeted and biologic therapies, healthcare advocacy, and nurturing caregivers.
Genitope Corporation's lead product candidate, MyVax personalized immunotherapy, is a patient-specific active immunotherapy
based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells.
B-cell malignancies are good candidates for active immunotherapy
The CAS found no differences in asthma symptoms between the active immunotherapy
and placebo groups.
This novel peptide is significant because it could provide the basis for an active immunotherapy
that uses T-cells to attack and destroy cancer cells that overexpress the HER-2 antigen," stated Gail Maderis, president of Genzyme Molecular Oncology.
Immunocellular Therapeutics, who will present the latest clinical results in utilizing active immunotherapy
against cancer stem cells in solid tumors
Researchers hypothesize that reducing alpha-synuclein accumulation will be neuroprotective; Affiris is using active immunotherapy
to test that theory and develop a disease-modifying treatment.
OBI-822 is an active immunotherapy
combining Globo-H, a carbohydrate antigen frequently expressed by cancer cells, jointly with KLH as the immune-stimulating carrier molecule.